ArticleJournal of cancer research and clinical oncology2012
Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Article in Journal of cancer research and clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.PloS one · 2017Pooled it
- A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules.Genomics, proteomics & bioinformatics · 2025Article
- Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review.Cell death discovery · 2019Review
- A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.International journal of clinical oncology · 2015Article
- Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer.Clinical and experimental immunology · 2014Article
- Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Peptides from the variable region of specific antibodies are shared among lung cancer patients.PloS one · 2014Article
- Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- A study of circulating anti-CD25 antibodies in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study was undertaken to test circulating autoantibody to ATP-binding cassette C3 (ABCC3) transporter in order to confirm whether anti-ABCC3 antibody could serve as a biomarker for early diagnosis of lung cancer.
methodsThis study recruited 275 patients (178 males and 97 females) with non-small cell lung cancer (either squamous carcinoma or adenocarcinoma) and 226 control subjects (134 males and 92 females) well matched in age and smoking history. Anti-ABCC3 IgA and IgG were determined using an enzyme-linked immunosorbent assay (ELISA) approach that was developed in house with the human leukocyte antigen class II (HLA-II) restricted antigens.
resultsMann-Whitney U test showed that the IgG antibody level was significantly higher in female patients with adenocarcinoma than female controls (Z = -4.34, P < 0.001) and that the IgA antibody level was significantly higher in male patients with squamous carcinoma than male controls (Z = -3.12, P = 0.002). Pearson's Chi-square (χ(2)) test showed that female patients with adenocarcinoma had a significantly higher positive rate for IgG autoantibody than female controls (χ ( 2 ) = 8.73, P = 0.003). The ELISA sensitivity against a specificity of >95 % was 18.1 % for IgG assay in female patients and 18.0 % for IgA assay in male patients. The inter-assay deviation was 10.6 % for IgG assay and 14.5 % for IgA assay.
conclusionsCirculating autoantibodies to ABCC3 transporter may be a potential biomarker that can be added to a panel of existing biomarkers for early diagnosis and prognosis of lung cancer although the gender differences should be taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.